Merck's Q1 2013 earnings call revealed significant near-term headwinds, primarily due to patent expirations impacting key products like Singulair, Maxalt, Clarinex, and Propecia.  Management, while acknowledging the challenges, emphasized their commitment to shareholder return, highlighted robust growth in emerging markets and vaccines, and announced a substantial share repurchase program.  The lowered guidance, however, suggests short-term stock pressure.
[-1]
